Abstract
Although the currently available vaccines represent an outstanding success story in modern medicine and have had a dramatic effect on morbidity and mortality worldwide, it is clear that improvements are required in the current vaccine delivery technologies. Improvements are required to enable the successful development of vaccines against infectious diseases that have so far proven difficult to control with conventional approaches. Improvements may include the addition of novel injectable adjuvants or the use of novel routes of delivery, including mucosal immunization. Mucosal delivery may be required to provide protection against pathogens that infect at mucosal sites, including sexually transmitted diseases. Alternatively, novel approaches to delivery, including mucosal administration, may be used to improve compliance for existing vaccines. Of particular interest for safer mass immunization campaigns are needle-free delivery devices, which would avoid problems due to needle re-use in many parts of the world and would avoid needle-stick injuries.
Article PDF
Similar content being viewed by others
REFERENCES
L. Jodar, P. Duclos, J. B. Milstien, E. Griffiths, M. T. Aguado, and C. J. Clements. Ensuring vaccine safety in immunization programmes–rspective. Vaccine 19:1594-1605 (2001).
N. M. Valiante, D. O'Hagan. and J. Ulmer. Innate Immunity and biodefence vaccines. Cell. Microbiol. 5:755-760 (2003).
J. M. Polo and T. W. Dubensky. Virus-based vectors for human vaccine applications. Drug Discov. Today 7:719-727 (2002).
G. Ramon. Procedures pour accroitre la production des antitoxines. Annales de l'Institut Pasteur 40:1-10 (1926).
R. Medzhitov and C. A. Janeway Jr. An ancient system of host defense. Curr. Opin. Immunol. 10:12-15 (1998).
A. Bendelac and R. Medzhitov. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med. 195:F19-F23 (2002).
R. Medzhitov. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:135-145 (2001).
D. T. O'Hagan and N. M. Valiante. Recent advances in the discovery and delivery of vaccines and adjuvants. Nat. Rev. Drug Discov. 2:727-735 (2003).
F. R. Vogel and M. F. Powell. A compendium of vaccine adjuvants and excipients. In M. F. Powelland M. J. Newman (eds), Vaccine Design: The Subunit and Adjuvant Approach, Plenum Press, New York, 1995, pp. 141-228.
R. M. Zinkernagel, S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengartner. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156:199-209 (1997).
R. Edelman. Adjuvants for the future. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds), New Generation Vaccines, Vol. Second, Marcel Dekker, Inc., New York, 1997, pp. 173-192.
R. T. Kenney and R. Edelman. Survey of human-use adjuvants. Expert Review Vaccines 2:167-188 (2003).
G. Ott. The Adjuvant MF59: A ten year perspective. In D. O'Hagan (ed), Vaccine Adjuvants; Preparation methods and research protocols (D. O'Hagan, ed), Humana Press, 2001, pp. 211-228.
M. Dupuis, K. Denis-Mize, A. LaBarbara, W. Peters, I. F. Charo, D. M. McDonald, and G. Ott. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31:2910-2918 (2001).
A. Podda and G. Del Giudice. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2:197-203 (2003).
F. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59: 1317-1325 (1974).
V. F. Vidal, N. Casteran, C. J. Riendeau, H. Kornfeld, E. C. Darcissac, A. Capron, and G. M. Bahr. Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4. Eur. J. Immunol. 31:1962-1971 (2001).
J. Wintsch, C. L. Chaignat, D. G. Braun, M. Jeannet, H. Stalder, S. Abrignani, D. Montagna, F. Clavijo, P. Moret, J. M. Dayer, et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis. 163:219-225 (1991).
W. Keitel, R. Couch, N. Bond, S. Adair, G. Van Nest, and C. Dekker. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11:909-913 (1993).
M. C. Keefer, B. S. Graham, M. J. McElrath, T. J. Matthews, D. M. Stablein, L. Corey, P. F. Wright, D. Lawrence, P. E. Fast, K. Weinhold, R. H. Hsieh, D. Chernoff, C. Dekker, and R. Dolin. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12:683-693 (1996).
J. O. Kahn, F. Sinangil, J. Baenziger, N. Murcar, D. Wynne, R. L. Coleman, K. S. Steimer, C. L. Dekker, and D. Chernoff. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170:1288-1291 (1994).
A. Banzhoff, P. Nacci, and A. Podda. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49:177-184 (2003).
K. G. Nicholson, A. E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma, and M. C. Zambon. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943 (2001).
C. K. Cunningham, D. W. Wara, M. Kang, T. Fenton, E. Hawkins, J. McNamara, L. Mofenson, A. M. Duliege, D. Francis, E. J. McFarland, and W. Borkowsky. Safety of 2 recombinant human immunodeficiency virus type 1 (hiv-1) envelope vaccines in neonates born to hiv-1-infected women. Clin. Infect. Dis. 32:801-807 (2001).
D. K. Mitchell, S. J. Holmes, R. L. Burke, A. M. Duliege, and S. P. Adler. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J. 21:133-138 (2002).
D. M. Granoff, Y. E. McHugh, H. V. Raff, A. S. Mokatrin, and G. A. Van Nest. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immun. 65:1710-1715 (1997).
G. Ott. Vaccine Design: The Subunit and Adjuvant Approach, Plenum Press, New York, 1995.
G. Ott, R. Radhakrishnan, J.-H. Fang, and M. Hora. The adjuvant MF59: a 10-year perspective. In D. T. O'Hagan (ed), Vaccine Adjuvants: Preparation Methods and Research Protocols (D. T. O'Hagan, ed), Humana Press Inc., Totowa, NJ, 2000, pp. 211-228.
D. T. O'Hagan, M. Singh, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and G. Ott. Synergistic adjuvant activity of immuno-stimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20:3389-3398 (2002).
S. Cherpelis, I. Shrivastava, A. Gettie, X. Jin, D. D. Ho, S. W. Barnett, and L. Stamatatos. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/ human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J. Virol. 75:1547-1550 (2001).
A. V. E. G. P. T.-. AIDS. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis. 183:563-570 (2001).
O. L. Johnson, J. L. Cleland, H. J. Lee, M. Charnis, E. Duenas, W. Jaworowicz, D. Shepard, A. Shahzamani, A. J. Jones, and S. D. Putney. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2:795-799 (1996).
Y. Tabata and Y. Ikada. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo-and copolymers. J. Biomed. Mater. Res. 22:837-858 (1988).
K. D. Newman, P. Elamanchili, G. S. Kwon and J. Samuel. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. 60:480-486 (2002).
G. J. Randolph, K. Inaba, D. F. Robbiani, R. M. Steinman, and W. A. Muller. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 11:753-761 (1999).
J. H. Eldridge, J. K. Staas, J. A. Meulbroek, T. R. Tice, and R. M. Gilley. Biodegradable and biocompatible poly(DL-lactide-coglycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59:2978-2986 (1991).
D. T. O'Hagan, D. Rahman, J. P. McGee, H. Jeffery, M. C. Davies, P. Williams, S. S. Davis, and S. J. Challacombe. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73:239-242 (1991).
K. J. Maloy, A. M. Donachie, D. T. O'Hagan, and A. M. Mowat. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81:661-667 (1994).
A. Moore, P. McGuirk, S. Adams, W. C. Jones, J. P. McGee, D. T. O'Hagan, and K. H. Mills. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 13:1741-1749 (1995).
L. D. Falo, M. Kovacsovicsbankowski, K. Thompson, and K. L. Rock. Targeting antigen into the phagocytic pathway in-vivo induces protective tumor-immunity. Nat. Med. 1:649-653 (1995).
D. T. O'Hagan. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34:305-320 (1998).
D. O'Hagan and M. S ingh. Microparticles as vaccine adjuvants and delivery systems. Expert Review Vaccines 2:269-283 (2003).
S. P. Schwendeman. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 19:73-98 (2002).
J. Kazzaz, J. Neidleman, M. Singh, G. Ott, and D. T. O'Hagan. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release 67:347-356 (2000).
G. R. Otten, M. Schaefer, C. Greer, M. Calderon-Cacia, D. Coit, J. Kazzaz, A. Medina-Selby, M. Selby, M. Singh, M. Ugozzoli, J. zur Megede, S. Barnett, D. O'Hagan, J. Donnelly, and J. B. Ulmer. Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J. Virol. 77:6087-6092 (2003).
M. Singh, J. Kazzaz, J. Chesko, E. Soenawan, M. Ugozzoli, M. M. Giuliani, M. Pizza, R. Rappuoli, and D. O'Hagan. Anionic microparticles are a potent delivery system for recombinant antigens from neisseria meningitidis serotype B. J. Pharm. Sci. 93: 273-282 (2004).
R. Wang, D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, M. Sedegah, C. de Taisne, J. A. Norman, and S. L. Hoffman. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476-480 (1998).
T. P. Le, K. M. Coonan, R. C. Hedstrom, Y. Charoenvit, M. Sedegah, J. E. Epstein, S. Kumar, R. Wang, D. L. Doolan, J. D. Maguire, S. E. Parker, P. Hobart, J. Norman, and S. L. Hoffman. Safety, tolerability and humoral immune responses after intra-muscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18:1893-1901 (2000).
X. Martinez, C. Brandt, F. Saddallah, C. Tougne, C. Barrios, F. Wild, G. Dougan, P. H. Lambert, and C. A. Siegrist. DNA immunization circumvents deficient induction of t helper type 1 and cytotoxic t lymphocyte responses in neonates and during early life. Proc.s Natl. Acad. Sci. USA 94:8726-8731 (1997).
M. Singh, M. Briones, G. Ott, and D. O'Hagan. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA 97:811-816 (2000).
D. O'Hagan, M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, M. Schaefer, B. Doe, G. R. Otten, and J. B. Ulmer. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 75:9037-9043 (2001).
K. S. Denis-Mize, M. Dupuis, M. L. MacKichan, M. Singh, B. Doe, D. O'Hagan, J. B. Ulmer, J. J. Donnelly, D. M. McDonald, and G. Ott. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7:2105-2112 (2000).
K. Denis-Mize, M. Dupuis, M. Singh, C. Woo, M. Ugozzoli, D. O'Hagan, J. Donnelly, G. Ott, and D. M. McDonald. Mechanisms of Increased Immunogenicity for DNA-Based Vaccines Absorbed onto Cationic Microparticles. Cell. Immunol. 225:12-20 (2003).
M. L. Hedley, J. Curley, and R. Urban. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 4:365-368 (1998).
S. Ando, D. Putnam, D. W. Pack, and R. Langer. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. 88:126-130 (1999).
D. O'Hagan, M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, G. R. Otten, and J. B. Ulmer. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol. 75:9037-9043 (2001).
M. Briones, M. Singh, M. Ugozzoli, J. Kazzaz, S. Klakamp, G. Ott, and D. O'Hagan. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res. 18:709-711 (2001).
M. Singh, M. Ugozzoli, M. Briones, J. Kazzaz, E. Soenawan, and D. O'Hagan. The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm. Res. 20:244-248 (2003).
M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D. T. O'Hagan. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. 18:1476-1479 (2001).
G. Ott, M. Singh, J. Kazzaz, M. Briones, E. Soenawan, M. Ugozzoli, and D. T. O'Hagan. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J. Control. Release 79:1-5 (2002).
S. M. Michalek, D. T. O'Hagan, S. Gould-Fogerite, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus. Antigen delivery systems: nonliving microparticles, liposomes, cochleates, and IS-COMS. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstrock, and J. R. McGhee (eds), Mucosal Immunology, Academic Press, San Diego, 1999, pp. 759-778.
M. Singh and D. T. O'Hagan. Recent advances in vaccine adjuvants. Pharm. Res. 19:715-728 (2002).
R. Rappuoli, M. Pizza, G. Douce, and G. Dougan. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20:493-500 (1999).
M. Pizza, M. M. Giuliani, M. R. Fontana, E. Monaci, G. Douce, G. Dougan, K. H. Mills, R. Rappuoli, and G. Del Giudice. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541 (2001).
H. Jakobsen, S. Bjarnarson, G. Del Giudice, M. Moreau, C. A. Siegrist, and I. Jonsdottir. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immun. 70:1443-1452 (2002).
S. Peppoloni, P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, R. Rappuoli, A. Podda, and G. Del Giudice. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Review Vaccines 2:285-293 (2003).
B. C. Baudner, O. Balland, M. M. Giuliani, P. Von Hoegen, R. Rappuoli, D. Betbeder, and G. Del Giudice. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun. 70:4785-4790 (2002).
M. Singh, M. Briones, and D. T. O'Hagan. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control. Release 70:267-276 (2001).
M. Ugozzoli, G. Santos, J. Donnelly, and D. T. O'Hagan. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J. Infect. Dis. 183:351-354 (2001).
K. H. Mills, C. Cosgrove, E. A. McNeela, A. Sexton, R. Giemza, I. Jabbal-Gill, A. Church, W. Lin, L. Illum, A. Podda, R. Rappuoli, M. Pizza, G. E. Griffin, and D. J. Lewis. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immuno-globulin a. Infect. Immun. 71:726-732 (2003).
B. C. Baudner, M. M. Giuliani, J. C. Verhoef, R. Rappuoli, H. E. Junginger, and G. D. Giudice. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21:3837-3844 (2003).
G. Douce, V. Giannelli, M. Pizza, D. Lewis, P. Everest, R. Rappuoli, and G. Dougan. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67:4400-4406 (1999).
J. D. Barackman, G. Ott, S. Pine, and D. T. O'Hagan. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 8:652-657 (2001).
J. D. Clemens, D. A. Sack, J. R. Harris, F. Van Loon, J. Chakraborty, F. Ahmed, M. R. Rao, M. R. Khan, M. Yunus, N. Huda, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335:270-273 (1990).
M. Jertborn, C. Ahren, J. Holmgren, and A. M. Svennerholm. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 16:255-260 (1998).
M. A. Van Deusen, B. L. Angelini, K. M. Cordoro, B. A. Seiler, L. Wood, and D. P. Skoner. Efficacy and safety of oral immunotherapy with short ragweed extract. Ann. Allergy Asthma Immunol. 78:573-580 (1997).
D. O'Hagan. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34:305-320 (1998).
S. L. Jain, K. S. Barone, M. P. Flanagan, and J. G. Michael. Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen. Vaccine 14:1291-1297 (1996).
D. E. Katz, A. J. DeLorimier, M. K. Wolf, E. R. Hall, F. J. Cassels, J. E. van Hamont, R. L. Newcomer, M. A. Davachi, D. N. Taylor, and C. E. McQueen. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21:341-346 (2003).
J. Holmgren, C. Czerkinsky, K. Eriksson, and A. Mharandi. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21:S89-S95 (2003).
A. B. Sabin, A. Flores Arechiga, J. Fernandez de Castro, J. L. Sever, D. L. Madden, I. Shekarchi, and P. Albrecht. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 249:2651-2662 (1983).
A. Dilraj, F. T. Cutts, J. F. de Castro, J. G. Wheeler, D. Brown, C. Roth, H. M. Coovadia, and J. V. Bennett. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355: 798-803 (2000).
F. T. Cutts, A. Henao-Restrepo, and J. M. Olive. Measles elimination: progress and challenges. Vaccine 17:S47-S52 (1999).
J. Sepulveda-Amor, J. L. Valdespino-Gomez, L. Garcia-Garcia Mde, J. Bennett, R. Islas-Romero, G. Echaniz-Aviles, and J. F. de Castro. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 20:2790-2795 (2002).
J. Canter, K. Mackey, L. S. Good, R. R. Roberto, J. Chin, W. W. Bond, M. J. Alter, and J. M. Horan. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch. Intern. Med. 150:1923-1927 (1990).
L. A. Jackson, G. Austin, R. T. Chen, R. Stout, F. DeStefano, G. J. Gorse, F. K. Newman, O. Yu, and B. G. Weniger. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19:4703-4709 (2001).
I. Parent du Chatelet, J. Lang, M. Schlumberger, E. Vidor, G. Soula, A. Genet, S. M. Standaert, and P. Saliou. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group. Vaccine 15:449-458 (1997).
D. Chen, R. L. Endres, C. A. Erickson, K. F. Weis, M. W. McGregor, Y. Kawaoka, and L. G. Payne. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6:1187-1190 (2000).
D. Chen, R. Endres, Y. F. Maa, C. R. Kensil, P. Whitaker-Dowling, A. Trichel, J. S. Youngner, and L. G. Payne. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21:2830-2836 (2003).
Y. F. Maa, L. Zhao, L. G. Payne, and D. Chen. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J. Pharm. Sci. 92:319-332 (2003).
J. E. Epstein, E. J. Gorak, Y. Charoenvit, R. Wang, N. Freydberg, O. Osinowo, T. L. Richie, E. L. Stoltz, F. Trespalacios, J. Nerges, J. Ng, V. Fallarme-Majam, E. Abot, L. Goh, S. Parker, S. Kumar, R. C. Hedstrom, J. Norman, R. Stout, and S. L. Hoffman. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum. Gene Ther. 13:1551-1560 (2002).
M. J. Roy, M. S. Wu, L. J. Barr, J. T. Fuller, L. G. Tussey, S. Speller, J. Culp, J. K. Burkholder, W. F. Swain, R. M. Dixon, G. Widera, R. Vessey, A. King, G. Ogg, A. Gallimore, J. R. Haynes, and D. Heydenburg Fuller. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19:764-778 (2000).
T. C. Heineman, M. L. Clements-Mann, G. A. Poland, R. M. Jacobson, A. E. Izu, D. Sakamoto, J. Eiden, G. A. Van Nest, and H. H. Hsu. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17:2769-2778 (1999).
M. J. McCluskie, C. L. Brazolot Millan, R. A. Gramzinski, H. L. Robinson, J. C. Santoro, J. T. Fuller, G. Widera, J. R. Haynes, R. H. Purcell, and H. L. Davis. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5:287-300 (1999).
J. Arrington, R. P. Braun, L. Dong, D. H. Fuller, M. D. Macklin, S. W. Umlauf, S. J. Wagner, M. S. Wu, L. G. Payne, and J. R. Haynes. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol. 76:4536-4546 (2002).
J. A. Mikszta, J. B. Alarcon, J. M. Brittingham, D. E. Sutter, R. J. Pettis, and N. G. Harvey. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8:415-419 (2002).
J. A. Matriano, M. Cormier, J. Johnson, W. A. Young, M. Buttery, K. Nyam, and P. E. Daddona. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 19:63-70 (2002).
G. M. Glenn, M. Rao, G. R. Matyas, and C. R. Alving. Skin immunization made possible by cholera toxin. Nature 391:851 (1998).
G. M. Glenn, D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403-1406 (2000).
F. Guerena-Burgueno, E. R. Hall, D. N. Taylor, F. J. Cassels, D. A. Scott, M. K. Wolf, Z. J. Roberts, G. V. Nesterova, C. R. Alving, and G. M. Glenn. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70:1874-1880 (2002).
T. Scharton-Kersten, J. Yu, R. Vassell, D. O'Hagan, C. R. Alving, and G. M. Glenn. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:5306-5313 (2000).
R. Tierney, A. S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. D. Partidos. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188:753-758 (2003).
M. Guebre-Xabier, S. A. Hammond, D. E. Epperson, J. Yu, L. Ellingsworth, and G. M. Glenn. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77:5218-5225 (2003).
G. Dziekan, D. Chisholm, B. Johns, J. Rovira, and Y. J. Hutin. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings. Bull. World Health Organ. 81:277-285 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Hagan, D.T., Rappuoli, R. Novel Approaches to Vaccine Delivery. Pharm Res 21, 1519–1530 (2004). https://doi.org/10.1023/B:PHAM.0000041443.17935.33
Issue Date:
DOI: https://doi.org/10.1023/B:PHAM.0000041443.17935.33